Juvéderm: What we know now

Abstract

AbstractIntroduction: The Juvéderm family of dermal fillers are injectable, long‐lasting, homogenous, monophasic, monodensified hyaluronic acid fillers which are cross‐linked with varying amounts of 1,4‐butanediol‐diglycidyl‐ether (BBDE). Several formulations of Juvéderm exist, including the original Juvéderm Ultra® and Juvéderm Ultra Plus®, and the newer Juvéderm Voluma® XC. Differences in the Juvéderm product line stem from the hyaluronic acid (HA) concentration, gel hardness (G star (G*)), elastic properties (G prime (G′)), amount of molecular cross‐linking (BBDE percentage), and technology utilized for cross‐linking. Discussion: The Juvéderm filler lineup is such that each product is uniquely formulated for a specific indication. The lineup together has shown to be efficacious in treating superficial lines to deep‐seated wrinkles. These fillers are unlikely to cause adverse immune reactions, and as with other HAFs, their effects can be reversed with the injection of hyaluronidase. Conclusion: This chapter discusses the variety of fillers currently in the market within the Juvéderm family, as well as several new products on the horizon. We detail product FDA approvals, indications, safety, and adverse events.